Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5403_Библиотеки_им_академика_М_И_Перельмана
.pdf
Smart Drug Delivery Systems – Futuristic Window in Cancer Therapy
101
https://t.me/med1917
Cancer Type Source Drug Delivery
Metastatic
Pancreatic
Adenocarcinoma
Pancreatic Cancer Exosome-
Head and Neck
Cancer
Advanced
Hepatocellular
Carcinoma
Colon Cancer Plant Curcumin Phase I NCT01294072 Unknown
Non-Small Cell
Lung Cancer
Malignant Glioma Tumor cells IGF-1R/
Table 1.
The recent clinical trials of exosomes as a drug delivery vehicle in cancer.
Mesenchymal
stem cell
mediated
Intercellular
Signaling
Plant Grape
Cell-derived
exosomes
Dendritic cells Vaccination
System
KrasG12D
siRNA
(iExosomes)
exosomes
exoASO-STAT6
(CDK-004)
With Tumor
Antigen-loaded
Dendritic
Cell-derived
Exosomes
AS ODN)exosomes
Clinical
Phase
Phase I NCT03608631 Recruiting
Phase I NCT01668849 Completed
Phase I NCT05375604 Terminated
Phase II NCT01159288 Completed
Phase I NCT02507583
ClinicalTrials.
gov ID
NCT02393703 Recruiting
NCT01550523
Status
Completed
. Conclusion
In summary, exosomes have emerged as promising nanoscale vesicles for targeted
drug delivery in cancer treatment. Their unique composition, small size, and inherent tumor-targeting ability make them valuable vehicles for delivering therapeutic
substances to tumors. This chapter has discussed the isolation methods, therapeutic
loading techniques, and the key role of exosomes in the tumor microenvironment.
The use of exosomes as drug delivery systems holds great potential for minimizing cytotoxic effects on healthy cells, while effectively delivering treatments to
cancercells.
. Future prospective
There are numerous prospective implications for exosome-based smart delivery
of drugs in cancer treatment. First, further research is needed to optimize the isolation and purification techniques of exosomes to ensure consistent quality and scalability for clinical applications. Second, exploring alternative methods for loading
therapeutic agents onto exosomes, such as genetic engineering or bioconjugation
strategies, could enhance drug encapsulation efficiency and therapeutic efficacy.
Third, understanding the mechanisms of exosome-mediated cellular communication
within the tumor microenvironment can open avenues for designing more targeted
Exosome-Based Smart Drug Delivery for Cancer Treatment
102
https://t.me/med1917
DOI: http://ITexLi.113744
and personalized treatments. Additionally, exosome’s potential as diagnostic tools for
early cancer detection and monitoring treatment response may also be investigated.
Overall, with continued advancements in exosome research, we anticipate exosomebased smart drug delivery systems to revolutionize cancer treatment by providing
more effective and tailored therapies in the near future.
Acknowledgements
This work was partially funded by Start-up from Department of Immunology and
Microbiology, School of Medicine, University of Texas Rio Grande Valley, and NIH
grants (R01 CA210192 and R01 CA206069). Authors thank the CPRIT (RP210180 and
RP230419) and UT-System Star Award.
Author contributions
Original draft preparation: S.M. and M.S., Editing: S.K. and M.M.Y., Final
proofreading and supervision: S.C.C. All authors have read and approved the final
manuscript.
Smart Drug Delivery Systems – Futuristic Window in Cancer Therapy
103
https://t.me/med1917
References
[1] Patel GK et al. Pancreatic cancer
exosomes: Shedding off for a meaningful
journey. Pancreatic Disorders and
Therapy. 2016;(2):e148
[2] Massey AE et al. Clinical implications
of exosomes: Targeted drug delivery for
cancer treatment. International Journal
of Molecular Sciences. 2021;(10):1-19
[3] Théry C, Zitvogel L, Amigorena S.
Exosomes: Composition, biogenesis and
function. Nature Reviews. Immunology.
2002;(8):569-579
[4] Bastos N et al. Exosomes in cancer:
Use them or target them? Seminars
in Cell & Developmental Biology.
2018;:13-21
[5] Kooijmans SA et al. Exosome
mimetics: A novel class of drug delivery
systems. International Journal of
Nanomedicine. 2012;:1525-1541
[6] Zhang L, Yu D. Exosomes in cancer
development, metastasis, and immunity.
Biochimica Et Biophysica Acta. Reviews
on Cancer. 2019;(2):455-468
[7] Lobb RJ et al. Optimized exosome
isolation protocol for cell culture
supernatant and human plasma. Journal
of Extracellular Vesicles. 2015;:27031
[8] Livshits MA et al. Isolation of
exosomes by differential centrifugation:
Theoretical analysis of a commonly
used protocol. Scientific Reports.
2015;:17319
[9] Tauro BJ et al. Comparison of
ultracentrifugation, density gradient
separation, and immunoaffinity
capture methods for isolating human
colon cancer cell line LIM1863-derived
exosomes. Methods. 2012;(2):293-304
[10] Ferreira D, Moreira JN,
Rodrigues LR. New advances in exosomebased targeted drug delivery systems.
Critical Reviews in Oncology/
Hematology. 2022;:103628
[11] Alvarez ML et al. Comparison of
protein, microRNA, and mRNA yields
using different methods of urinary
exosome isolation for the discovery
of kidney disease biomarkers. Kidney
International. 2012;(9):1024-1032
[12] Kimiz-Gebologlu I, Oncel SS.
Exosomes: Large-scale production,
isolation, drug loading efficiency, and
biodistribution and uptake. Journal of
Controlled Release. 2022;:533-543
[13] Cheruvanky A et al. Rapid isolation
of urinary exosomal biomarkers
using a nanomembrane ultrafiltration
concentrator. American Journal
of Physiology. Renal Physiology.
2007;(5):F1657-F1661
[14] Batrakova EV, Kim MS. Using
exosomes, naturally-equipped
nanocarriers, for drug delivery. Journal
of Controlled Release. 2015;:396-405
[15] Greening DW et al. A protocol for
exosome isolation and characterization:
Evaluation of ultracentrifugation,
density-gradient separation, and
immunoaffinity capture methods.
Methods in Molecular Biology.
2015;:179-209
[16] Muller L et al. Isolation of
biologically-active exosomes from human
plasma. Journal of Immunological
Methods. 2014;:55-65
[17] Sidhom K, Obi PO, Saleem A.
Areview of exosomal isolation methods:
Is size exclusion chromatography
Exosome-Based Smart Drug Delivery for Cancer Treatment
DOI: http://ITexLi.113744
the best option? International
104
https://t.me/med1917
Journal of Molecular Sciences.
2020;(18):1525-1541
[18] Taylor DD, Zacharias W,
Gercel-Taylor C. Exosome isolation
for proteomic analyses and RNA
profiling. Methods in Molecular Biology.
2011;:235-246
[19] Chen C et al. Microfluidic
isolation and transcriptome analysis
of serum microvesicles. Lab on a
Chip. 2010;(4):505-511
[20] Yang D et al. Progress, opportunity,
and perspective on exosome isolation efforts for efficient exosome-based
theranostics. Theranostics. 2020;(8):
3684-3707
[21] Greco KA et al. PLK-1 silencing in
bladder cancer by siRNA delivered with
exosomes. Urology. 2016;:241.e1-241.e7
[22] Zhang D et al. Enrichment of
selective miRNAs in exosomes and
delivery of exosomal miRNAs in vitro
and in vivo. American Journal of
Physiology. Lung Cellular and Molecular
Physiology. 2017;(1):L110-l121
[23] Johnsen KB et al. A comprehensive
overview of exosomes as drug delivery
vehicles - endogenous nanocarriers for
targeted cancer therapy. Biochimica et
Biophysica Acta. 2014;(1):75-87
[24] Luan X et al. Engineering exosomes
as refined biological nanoplatforms for
drug delivery. Acta Pharmacologica
Sinica. 2017;(6):754-763
[25] Zhuang X et al. Treatment of brain
inflammatory diseases by delivering
exosome encapsulated anti-inflammatory
drugs from the nasal region to the brain.
Molecular Therapy. 2011;(10):1769-1779
cells and released in exosomes that
inhibit in vitro tumor growth: A new
approach for drug delivery. Journal of
Controlled Release. 2014;:262-270
[27] Fuhrmann G et al. Active loading
into extracellular vesicles significantly
improves the cellular uptake and
photodynamic effect of porphyrins.
Journal of Controlled Release.
2015;:35-44
[28] Podolak I, Galanty A, Sobolewska D.
Saponins as cytotoxic agents: A
review. Phytochemistry Reviews.
2010;(3):425-474
[29] Antimisiaris SG, Mourtas S,
Marazioti A. Exosomes and exosomeinspired vesicles for targeted drug
delivery. Pharmaceutics. 2018;(4):1-40
[30] Kim MS et al. Development of
exosome-encapsulated paclitaxel
to overcome MDR in cancer cells.
Nanomedicine. 2016;(3):655-664
[31] Sato YT et al. Engineering hybrid
exosomes by membrane fusion
with liposomes. Scientific Reports.
2016;:21933
[32] Wahlgren J et al. Plasma
exosomes can deliver exogenous short
interfering RNA to monocytes and
lymphocytes. Nucleic Acids Research.
2012;(17):e130
[33] Shtam TA et al. Exosomes are natural
carriers of exogenous siRNA to human
cells in vitro. Cell Communication and
Signaling: CCS. 2013;:88
[34] Katakowski M et al. Exosomes from
marrow stromal cells expressing miR146b inhibit glioma growth. Cancer
Letters. 2013;(1):201-204
[26] Pascucci L et al. Paclitaxel is
incorporated by mesenchymal stromal
[35] Paskeh MDA et al. Emerging role
of exosomes in cancer progression and
Smart Drug Delivery Systems – Futuristic Window in Cancer Therapy
105
https://t.me/med1917
tumor microenvironment remodeling.
Journal of Hematology & Oncology.
2022;(1):83
[36] Attaran S, Bissell MJ. The role of
tumor microenvironment and exosomes
in dormancy and relapse. Seminars in
Cancer Biology. 2022;:35-44
[37] Yokoi A, Ochiya T. Exosomes
and extracellular vesicles: Rethinking
the essential values in cancer
biology. Seminars in Cancer Biology.
2021;:79-91
[38] da Costa VR et al. Exosomes in the
tumor microenvironment: From biology to
clinical applications. Cell. 2021;(10):1-27
[39] Pathania AS, Prathipati P,
Challagundla KB. New insights into
exosome mediated tumor-immune
escape: Clinical perspectives and
therapeutic strategies. Biochimica Et
Biophysica Acta. Reviews on Cancer.
2021;(2):188624
[40] Lin W et al. Tumor-intrinsic
YTHDF1 drives immune evasion and
resistance to immune checkpoint
inhibitors via promoting MHC-I
degradation. Nature Communications.
2023;(1):265
[41] Taylor DD, Gerçel-Taylor C.
Tumour-derived exosomes and their
role in cancer-associated T-cell signalling
defects. British Journal of Cancer.
2005;(2):305-311
[42] Daassi D, Mahoney KM, Freeman GJ.
The importance of exosomal
PDL1 in tumour immune evasion.
Nature Reviews. Immunology.
2020;(4):209-215
[43] Vinay DS et al. Immune evasion in
cancer: Mechanistic basis and therapeutic
strategies. Seminars in Cancer Biology.
2015;(Suppl.):S185-s198
[44] Tie Y et al. Immunosuppressive
cells in cancer: Mechanisms and
potential therapeutic targets. Journal of
Hematology & Oncology. 2022;(1):61
[45] Bardi GT, Smith MA, Hood JL.
Melanoma exosomes promote mixed
M1 and M2 macrophage polarization.
Cytokine. 2018;:63-72
[46] Wang D et al. Exosome-encapsulated
miRNAs contribute to CXCL12/CXCR4induced liver metastasis of colorectal
cancer by enhancing M2 polarization
of macrophages. Cancer Letters.
2020; :36-52
[47] Biswas S et al. Exosomes produced
by mesenchymal stem cells drive
differentiation of myeloid cells into
immunosuppressive M2-polarized
macrophages in breast cancer. Journal of
Immunology. 2019;(12):3447-3460
[48] Wang X et al. Correction: Hypoxic
tumor-derived Exosomal miR-301a
mediates M2 macrophage polarization
via PTEN/PI3Kγ to promote pancreatic
cancer metastasis. Cancer Research.
2020;(4):922
[49] Lan J et al. M2 macrophage-derived
exosomes promote cell migration
and invasion in colon cancer. Cancer
Research. 2019;(1):146-158
[50] Varadé J, Magadán S,
González-Fernández Á. Human
immunology and immunotherapy:
Main achievements and challenges.
Cellular & Molecular Immunology.
2021;(4):805-828
[51] Sun C, Dotti G, Savoldo B.
Utilizing cell-based therapeutics to
overcome immune evasion in
hematologic malignancies. Blood.
2016;(26):3350-3359
[52] Zhang H et al. Exosomes as
smart drug delivery vehicles for
Exosome-Based Smart Drug Delivery for Cancer Treatment
DOI: http://ITexLi.113744
cancer immunotherapy. Frontiers in
106
https://t.me/med1917
Immunology. 2022;:1093607
[53] Wang H et al. MicroRNA-181d-
5p-containing exosomes derived from
CAFs promote EMT by regulating
CDX2/HOXA5 in breast cancer.
Molecular Therapy - Nucleic Acids.
2020;:654-667
[54] Hoshino A et al. Tumour
exosome integrins determine
organotropic metastasis. Nature.
2015;(7578):329-335
[55] Yuan X et al. Breast cancer
exosomes contribute to pre-metastatic
niche formation and promote bone
metastasis of tumor cells. Theranostics.
2021;(3):1429-1445
[56] Karampoga A et al. Exosomes and
the extracellular matrix: A dynamic
interplay in cancer progression. The
International Journal of Developmental
Biology. 2022;(1-2-3):97-102
[57] Neophytou CM et al. The role of
tumor microenvironment in cancer
metastasis: Molecular mechanisms and
therapeutic opportunities. Cancers
(Basel). 2021;(9):1-22
[58] Wang J et al. Microenvironment-
induced TIMP2 loss by cancer-secreted
exosomal miR-4443 promotes
liver metastasis of breast cancer.
Journal of Cellular Physiology.
2020;(7-8):5722-5735
[59] Dai J et al. Exosomes: Key players in
cancer and potential therapeutic strategy.
Signal Transduction and Targeted
Therapy. 2020;(1):145
[60] Gao Z et al. Drug-resistant cancer
cell-derived exosomal EphA2 promotes
breast cancer metastasis via the EphA2Ephrin A1 reverse signaling. Cell Death
& Disease. 2021;(5):414
[61] Chen C et al. Exosomal long
noncoding RNA LNMAT2 promotes
lymphatic metastasis in bladder cancer.
The Journal of Clinical Investigation.
2020;(1):404-421
[62] Haider T et al. Drug resistance
in cancer: Mechanisms and tackling
strategies. Pharmacological Reports.
2020;(5):1125-1151
[63] Mashouri L et al. Exosomes:
Composition, biogenesis, and
mechanisms in cancer metastasis and
drug resistance. Molecular Cancer.
2019;(1):75
[64] Azmi AS, Bao B, Sarkar FH.
Exosomes in cancer development,
metastasis, and drug resistance: A
comprehensive review. Cancer Metastasis
Reviews. 2013;(3-4):623-642
[65] Milman N, Ginini L, Gil Z. Exosomes
and their role in tumorigenesis and
anticancer drug resistance. Drug
Resistance Updates. 2019;:1-12
[66] Guo QR et al. The role of Exosomal
microRNA in cancer drug resistance.
Frontiers in Oncology. 2020;:472
[67] Yousafzai NA et al. Exosome
mediated multidrug resistance in cancer.
American Journal of Cancer Research.
2018;(11):2210-2226
[68] Zhong Y et al. Exosomes: A new
pathway for cancer drug resistance.
Frontiers in Oncology. 2021;:743556
[69] Wang X, Zhou Y, Ding K. Roles
of exosomes in cancer chemotherapy
resistance, progression, metastasis and
immunity, and their clinical applications
(review). International Journal of
Oncology. 2021;(1):1-18
[70] Wang X et al. Exosomes play an
important role in the process of psoralen
Smart Drug Delivery Systems – Futuristic Window in Cancer Therapy
107
https://t.me/med1917
reverse multidrug resistance of breast
cancer. Journal of Experimental &
Clinical Cancer Research. 2016;(1):186
[71] Olejarz W et al. Exosomes in
angiogenesis and anti-angiogenic therapy
in cancers. International Journal of
Molecular Sciences. 2020;(16):1-25
[72] He L et al. Ovarian cancer cell-
secreted exosomal miR-205 promotes
metastasis by inducing angiogenesis.
Theranostics. 2019;(26):8206-8220
[73] Shang D et al. Pancreatic cancer
cell-derived exosomal microRNA-27a
promotes angiogenesis of human
microvascular endothelial cells in
pancreatic cancer via BTG2. Journal
of Cellular and Molecular Medicine.
2020; (1):588-604
[74] Duan B et al. Exosomal miR-17-5p
promotes angiogenesis in nasopharyngeal
carcinoma via targeting BAMBI. Journal
of Cancer. 2019;(26):6681-6692
[75] Guarino BD et al. Extracellular
vesicles from pathological
microenvironment induce endothelial
cell transformation and abnormal
angiogenesis via modulation of
TRPV4 channels. Frontiers in Cell and
Development Biology. 2019;:344
[76] Whiteside TL. Tumor-derived
exosomes and their role in cancer
progression. Advances in Clinical
Chemistry. 2016;:103-141
[77] Valadi H et al. Exosome-mediated
transfer of mRNAs and microRNAs is a
novel mechanism of genetic exchange
between cells. Nature Cell Biology.
2007;(6):654-659
[78] Liu Q. The emerging roles of
exosomal long non-coding RNAs in
bladder cancer. Journal of Cellular and
Molecular Medicine. 2022;(4):966-976
[79] Wang M et al. The functional roles
of exosomal long non-coding RNAs
in cancer. Cellular and Molecular Life
Sciences. 2019;(11):2059-2076
[80] Wu Y et al. Advances in the study
of exosomal lncRNAs in tumors and
the selection of research methods.
Biomedicine & Pharmacotherapy.
2020;:109716
[81] Tripathi MK et al. Role of lncRNAs in
ovarian cancer: Defining new biomarkers
for therapeutic purposes. Drug Discovery
Today. 2018;(9):1635-1643
[82] Zhan Y et al. Expression signatures of
exosomal long non-coding RNAs in urine
serve as novel non-invasive biomarkers
for diagnosis and recurrence prediction
of bladder cancer. Molecular Cancer.
2018;(1):142
[83] Zhang S et al. Evaluation of serum
exosomal LncRNA-based biomarker
panel for diagnosis and recurrence
prediction of bladder cancer. Journal
of Cellular and Molecular Medicine.
2019;(2):1396-1405
[84] Wang J et al. Determination of
serum Exosomal H19 as a noninvasive
biomarker for bladder cancer diagnosis
and prognosis. Medical Science Monitor.
2018; :9307-9316
[85] Işın M et al. Exosomal lncRNA-p21
levels may help to distinguish prostate
cancer from benign disease. Frontiers in
Genetics. 2015;:168
[86] Zhang J et al. Exosomal long
noncoding RNAs are differentially
expressed in the cervicovaginal lavage
samples of cervical cancer patients.
Journal of Clinical Laboratory Analysis.
2016;(6):1116-1121
[87] Qiu JJ et al. Exosomal metastasis-
associated lung adenocarcinoma
Exosome-Based Smart Drug Delivery for Cancer Treatment
DOI: http://ITexLi.113744
transcript 1 promotes angiogenesis
108
https://t.me/med1917
and predicts poor prognosis in
epithelial ovarian cancer. International
Journal of Biological Sciences.
2018;(14):1960-1973
[88] Lin LY et al. Tumor-originated
exosomal lncUEGC1 as a circulating
biomarker for early-stage gastric cancer.
Molecular Cancer. 2018;(1):84
[89] Zhao R et al. Exosomal long
noncoding RNA HOTTIP as potential
novel diagnostic and prognostic
biomarker test for gastric cancer.
Molecular Cancer. 2018;(1):68
[90] Tan SK et al. Serum long noncoding
RNA HOTAIR as a novel diagnostic and
prognostic biomarker in glioblastoma
multiforme. Molecular Cancer.
2018;(1):74
[91] Li C et al. Tumor-derived exosomal
lncRNA GAS5 as a biomarker for
early-stage non-small-cell lung cancer
diagnosis. Journal of Cellular Physiology.
2019;(11):20721-20727
[92] Ren J et al. Carcinoma-associated
fibroblasts promote the stemness and
chemoresistance of colorectal cancer
by transferring exosomal lncRNA H19.
Theranostics. 2018;(14):3932-3948
[93] Li B et al. Exosome-mediated
transfer of lncRUNX2-AS1 from
multiple myeloma cells to MSCs
contributes to osteogenesis. Oncogene.
2018;(41):5508-5519
[94] Xue M et al. Hypoxic exosomes
facilitate bladder tumor growth and
development through transferring long
non-coding RNA-UCA1. Molecular
Cancer. 2017;(1):143
[95] Song W et al. Tumor-derived
extracellular vesicles in angiogenesis.
Biomedicine & Pharmacotherapy.
2018;:1203-1208
[96] Lang HL et al. Glioma cells enhance
angiogenesis and inhibit endothelial
cell apoptosis through the release of
exosomes that contain long non-coding
RNA CCAT2. Oncology Reports.
2017;(2):785-798
[97] Ma X et al. Long non-coding
RNA HOTAIR enhances angiogenesis
by induction of VEGFA expression
in glioma cells and transmission
to endothelial cells via glioma cell
derived-extracellular vesicles. American
Journal of Translational Research.
2017;(11):5012-5021
[98] Zhang W et al. Exosome-mediated
transfer of lncRNA RP11-838N2.4
promotes erlotinib resistance in nonsmall cell lung cancer. International
Journal of Oncology. 2018;(2):527-538
[99] Zhang R et al. Serum long non
coding RNA MALAT-1 protected by
exosomes is up-regulated and promotes
cell proliferation and migration in nonsmall cell lung cancer. Biochemical and
Biophysical Research Communications.
2017;(2):406-414
[100] Zhang P et al. Exosome-mediated
delivery of MALAT1 induces cell
proliferation in breast cancer. Oncotargets
and Therapy. 2018;:291-299
[101] Gao T et al. Exosomal lncRNA 91H
is associated with poor development in
colorectal cancer by modifying HNRNPK
expression. Cancer Cell International.
2018;:11
[102] Li Z et al. Tumor-derived exosomal
lnc-Sox2ot promotes EMT and stemness
by acting as a ceRNA in pancreatic
ductal adenocarcinoma. Oncogene.
2018;(28):3822-3838
Smart Drug Delivery Systems – Futuristic Window in Cancer Therapy
109
https://t.me/med1917
[103] Li W et al. Exosomal FMR1-AS1
facilitates maintaining cancer stem-like
cell dynamic equilibrium via TLR7/
NFκB/c-Myc signaling in female
esophageal carcinoma. Molecular Cancer.
2019;(1):22
[104] Xu CG et al. Exosomes mediated
transfer of lncRNA UCA1 results in
increased tamoxifen resistance in breast
cancer cells. European Review for
Medical and Pharmacological Sciences.
2016;(20):4362-4368
[105] Li Z et al. lncRNA UCA1 mediates
resistance to cisplatin by regulating the
miR-143/FOSL2-Signaling pathway in
ovarian cancer. Molecular Therapy Nucleic Acids. 2019;:92-101
[106] Yang YN et al. Predictive role
of UCA1-containing exosomes in
cetuximab-resistant colorectal cancer.
Cancer Cell International. 2018;:164
[107] Dong H et al. Exosome-mediated
transfer of lncRNA-SNHG14 promotes
trastuzumab chemoresistance in
breast cancer. International Journal of
Oncology. 2018;(3):1013-1026
[108] Kang M et al. Exosome-mediated
transfer of lncRNA PART1 induces
gefitinib resistance in esophageal
squamous cell carcinoma via functioning
as a competing endogenous RNA. Journal
of Experimental & Clinical Cancer
Research. 2018;(1):171
[111] Zhang W et al. The role of exosomal
lncRNAs in cancer biology and clinical
management. Experimental & Molecular
Medicine. 2021;(11):1669-1673
[112] Peng Q et al. Preformed
albumin corona, a protective
coating for nanoparticles based
drug delivery system. Biomaterials.
2013;(33):8521-8530
[113] Veronese FM et al. Polyethylene
glycol-superoxide dismutase, a conjugate
in search of exploitation. Advanced Drug
Delivery Reviews. 2002;(4):587-606
[114] Yang T et al. Exosome delivered
anticancer drugs across the blood-brain
barrier for brain cancer therapy in
Danio rerio. Pharmaceutical Research.
2015;(6):2003-2014
[115] Giallombardo M et al. Exosome-
mediated drug resistance in cancer:
The near future is here. Therapeutic
Advances in Medical Oncology.
2016;(5):320-322
[116] Zhao X et al. Exosomes as drug
carriers for cancer therapy and challenges
regarding exosome uptake. Biomedicine
& Pharmacotherapy. 2020;:110237
[117] Wang J, Zheng Y, Zhao M. Exosome-
based cancer therapy: Implication for
targeting cancer stem cells. Frontiers in
Pharmacology. 2016;:533
[109] Lei Y et al. Tumor-released lncRNA
H19 promotes gefitinib resistance via
packaging into exosomes in non-small
cell lung cancer. Oncology Reports.
2018;(6):3438-3446
[110] Qu L et al. Exosome-transmitted
lncARSR promotes Sunitinib resistance
in renal cancer by acting as a competing
endogenous RNA. Cancer Cell.
2016;(5):653-668
[118] Jang SC et al. Bioinspired
exosome-mimetic nanovesicles for
targeted delivery of chemotherapeutics
to malignant tumors. ACS Nano.
2013;(9):7698-7710
[119] Zhao N, Woodle MC,
Mixson AJ. Advances in delivery
systems for doxorubicin. Journal of
Nanomedicine and Nanotechnology.
2018;(5):1-22
Exosome-Based Smart Drug Delivery for Cancer Treatment
DOI: http://ITexLi.113744
[120] Smyth TJ et al. Examination of
110
https://t.me/med1917
the specificity of tumor cell derived
exosomes with tumor cells in vitro.
Biochimica et Biophysica Acta.
2014;(11):2954-2965
[128] Sedykh S, Kuleshova A, Nevinsky G.
Milk exosomes: Perspective agents for
anticancer drug delivery. International
Journal of Molecular Sciences.
2020;(18):1-16
[121] Hadla M et al. Exosomes increase
the therapeutic index of doxorubicin in
breast and ovarian cancer mouse models.
Nanomedicine (London, England).
2016;(18):2431-2441
[122] Wei H et al. A Nanodrug consisting
of doxorubicin and exosome derived
from mesenchymal stem cells for
osteosarcoma treatment In vitro.
International Journal of Nanomedicine.
2019;:8603-8610
[123] Mu Q et al. Stable and
efficient paclitaxel nanoparticles
for targeted glioblastoma therapy.
Advanced Healthcare Materials.
2015;(8):1236-1245
[124] Salarpour S et al. Paclitaxel
incorporated exosomes derived from
glioblastoma cells: Comparative study
of two loading techniques. Daru.
2019;(2):533-539
[129] Adriano B et al. Milk exosomes:
Nature’s abundant nanoplatform for
theranostic applications. Bioactive
Materials. 2021;(8):2479-2490
[130] Li D et al. Hyaluronan decoration
of milk exosomes directs tumor-specific
delivery of doxorubicin. Carbohydrate
Research. 2020;:108032
[131] Zhang J et al. Engineered
neutrophil-derived exosome-like vesicles
for targeted cancer therapy. Science
Advances. 2022;(2):eabj8207
[132] Carobolante G et al. Cow Milk
and intestinal epithelial cell-derived
extracellular vesicles as systems
for enhancing oral drug delivery.
Pharmaceutics. 2020;(3):1-11
[133] Agrawal AK et al. Milk-derived
exosomes for oral delivery of paclitaxel.
Nanomedicine. 2017;(5):1627-1636
[125] Ha D, Yang N, Nadithe V. Exosomes
as therapeutic drug carriers and delivery
vehicles across biological membranes:
Current perspectives and future
challenges. Acta Pharmaceutica Sinica B.
2016;(4):287-296
[126] Zhou W et al. Pancreatic cancer-
targeting exosomes for enhancing
immunotherapy and reprogramming
tumor microenvironment. Biomaterials.
2021;:120546
[127] Qambrani A et al. Biocompatible
exosomes nanodrug cargo for
cancer cell bioimaging and drug
delivery. Biomedical Materials.
2021;(2):025026
[134] Aggarwal BB, Harikumar KB.
Potential therapeutic effects of curcumin,
the anti-inflammatory agent, against
neurodegenerative, cardiovascular,
pulmonary, metabolic, autoimmune and
neoplastic diseases. The International
Journal of Biochemistry & Cell Biology.
2009;(1):40-59
[135] Dhillon N et al. Phase II trial of
curcumin in patients with advanced
pancreatic cancer. Clinical Cancer
Research. 2008;(14):4491-4499
[136] Sun D et al. A novel nanoparticle
drug delivery system: The antiinflammatory activity of curcumin
is enhanced when encapsulated
Соседние файлы в папке Библиотека им академика М.И. Перельмана